ADHD Alcobra Ltd.

1.06
-0.01  -1%
Previous Close 1.07
Open 1.06
Price To book 0.72
Market Cap 29216563
Shares 27,562,795
Volume 56,508
Short Ratio 14.80
Av. Daily Volume 75,256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 17, 2017 - failed to meet primary endpoint.
MDX (Metadoxine Extended Release (MG01CI))
Adult ADHD
Phase 2b data released March 2015. Secondary cognitive measures did not produce statistically significant results.
MDX (Metadoxine Extended Release (MG01CI))
Pediatric ADHD
Phase 2 trial did not meet endpoints - June 2015.
MDX (Metadoxine Extended Release (MG01CI))
Fragile X Syndrome